Introduction
Distal symmetric polyneuropathy or diabetic sensorimotor polyneuropathy (DSPN) is a frequent complication of both type 1 and type 2 diabetes [1]. DSPN encompasses a group of clinical and subclinical syndromes with varied etiologies and clinical and laboratorial manifestations, defined by the progressive diffuse or focal degeneration of peripheral somatic and autonomic nerve fibers [2].

Consensus definitions for DSPN consistently recommend a combination of neuropathic symptoms and signs, in addition to specific abnormalities in nerve conduction studies (NCS), as criteria for diagnosis [3,4]. The absence of symptoms should not be equated with the absence of neuropathy; up to 50% of patients with diabetic polyneuropathy may be asymptomatic but are still at risk of foot ulcers. Therefore, monitoring for neuropathy should be a regular part of the clinical care of patients with diabetes [5].

Several clinical scores have been developed to assess diabetic neuropathy, including the Diabetic Neuropathy Symptom (DNS) score [6], Neuropathy Symptom Score (NSS), Diabetic Neuropathy Examination (DNE), and Neuropathy Disability Score (NDS) [7].

Glycemic control may be considered as an auxiliary measure for predicting chronic diabetes mellitus complications, including DSPN. The clinical
measurement of glycosylated hemoglobin (HbA1c) is highly recommended for diabetes management. Maintaining HbA1c levels below 6.5% is a major goal of diabetes management, because HbA1c levels correlate well with diabetes complication risks [8].

The aim of the present study was to diagnose DSPN clinically in patients with type 2 diabetes using neurological examination scores, which are easy to perform, and to correlate these scores with electrophysiological measurements.

Patients and methods

Study population

Thirty patients diagnosed with type 2 diabetes (according to the American Diabetes Association criteria) [9] were included in the study. Patients were recruited from the Rheumatology and Rehabilitation department and diabetes outpatient clinic of Internal Medicine department. Ten healthy age-matched and sex-matched participants served as the control group for electrodiagnostic studies. Informed consent was obtained from all participants in the study. The study was approved by the ethics committee of the Faculty of Medicine.

Patients having any evidence of autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma), cervical and/or lumbar disc lesions, neuropathies of other etiologies (such as heredofamilial polyneuropathy, exposure to neurotoxic drugs, infections, or neuropathies due to other causes or renal failure) were excluded.

Neurological examination scores

We selected four scores on the basis of ease of performance and common use. The scores were DNS, modified NSS, DNE, and modified NDS [6,7].

Diabetic Neuropathy Symptom score

All participants were questioned as regards the presence of symptoms, either positive or negative, suggesting the presence of neuropathy.

The questions were answered with a ‘yes’ (positive: one point) if a symptom had occurred several times a week during the last 2 weeks, or with a ‘no’ (negative: no point) if it did not. The patients were questioned as regards the presence of following symptoms:

(1) Symptoms of unsteadiness when walking.
(2) Burning, aching pain, or tenderness in legs or feet.
(3) Pricking sensations on legs and feet.
(4) Regions of numbness on legs or feet.

Maximum score: 4 points; 0 points, polyneuropathy (PNP) absent; 1–4 points, PNP present [6].

Modified Neuropathy Symptom Score

Patients were questioned about the presence or absence of numbness, abnormal hot or cold sensations, tingling sensations, burning pain, irritation from bed clothes in the lower legs and feet, and nocturnal exacerbation of muscular cramps and whether maneuvers could reduce the symptoms. One point for the presence of each of these symptoms was assigned. For the first five symptoms one extra point was added if nocturnal exacerbation was present. The maximum score is 10 points. A score of more than 1 point is defined as positive for PNP [10] (Table 1).

Diabetic Neuropathy Examination score

The score contains two items for muscle strength, one pertaining to reflexes and five pertaining to sensation (eight total items). Each item is scored from 0 to 2 (0 is normal and 2 severely disturbed). The maximum score is 16 points. A score greater than 3 points is defined as positive for PNP [11] (Table 2).

Modified Neuropathy Disability Score

The modified NDS can be easily performed in the clinical setting and takes only a minute or two to complete and provides an assessment of the risk for neuropathic ulceration. The score is based on vibration perception, pin-prick sensation, temperature perception, and ankle

| Table 1 Modified NDS score |
|-----------------------------|
| Symptomatology: foot/lower leg | Yes | No |
| Burning sensation | 2 | 0 |
| Numbness | 2 | 0 |
| Paresthesia | 2 | 0 |
| Feeling of weakness (fatigue, exhaustion) | 1 | 0 |
| Cramps | 1 | 0 |
| Pain | 1 | 0 |
| Localization | | |
| Feet | 2 |
| Lower leg | 1 |
| Elsewhere | 0 |
| Exacerbation | | |
| Present at night | 2 |
| Present during day and night | 1 |
| Only present during the day | 0 |
| Patient is awakened from sleep by the symptoms | 1 add |
| Symptom improvement | | |
| Walking | 2 |
| Standing | 1 |
| Sitting or lying down | 0 |
| Total score | | |

In each point column, the maximum score can be given only once; 3–4, mild symptoms; 5–6, moderate symptoms; 7–10, severe neuropathic symptoms.
(Achilles) reflexes. The maximum deficit score is 10, which would indicate complete loss of sensation to all sensory modalities and absent reflexes. A score of 6 or more has been found to indicate an increased risk for foot ulceration [7,12] (Table 3).

The patients were diagnosed as having clinically detectable neuropathy (group I) if DNS was 1 or more, modified NSS was greater than 1, or DNE was greater than 3. Undetectable neuropathy (group II) was diagnosed if DNS was less than 1, modified NSS was 1 or less, or DNE was 3 or less. Modified NSS and modified NDS were used to quantify the severity of the neuropathy [13].

Nerve conduction studies

NCS were performed to all patients and controls at a room temperature of 23 ± 2°C. Nihon Kohden MEB-9400K NeuropackS1equipment (Nihon Kohden Corporation 1-31-4 Nishiochial, Shinjuku, Tokyo 161-8560, Japan) was used by the same electromyographer. Motor and sensory distal latencies, amplitudes, and nerve conduction velocities were measured in the upper and lower limb nerves. The simplified NCS protocol was followed to record the NCS of the patients [14].

Five nerves were tested (median, ulnar, tibial, common peroneal, and sural nerves). The NCS were used to identify normal or affected nerves. The patients were diagnosed as having polyneuropathy if the value of two or more parameters was abnormal in one nerve, or one parameter was abnormal in any two nerves. Amplitudes, velocities, and latencies of seven nerves — that is, four motor (median, ulnar, tibial, and common peroneal) and three sensory (median, ulnar, and sural) nerves — were recorded. An overall Nerve Conduction Sum score was defined as the number of these five nerves with an abnormal conduction velocity, ranging from 0 (all normal) to 7 (all abnormal) [15].

Grouping of patients on the basis of neurological score and nerve conduction studies

For each neurological score, patients were divided into four groups: true positive, false positive, false negative, and true negative. If neuropathy was present by both clinical examination and NCS, the patient was included in the true-positive group, in the false-positive group if it was present on clinical examination but was absent on NCS, in the false-negative group if it was present on NCS but was absent on clinical examination, and in the true-negative group if it was absent on both testing methods. The sensitivity and specificity of each score were calculated taking NCS as the gold standard. Data presented in Table 8 were used to calculate test performance characteristics. Diagnostic efficacy of each test was derived from the same data.

Statistical analysis

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) 16.0. Descriptive statistics were carried out using number and percentage, as well as mean and SD. The ANOVA test was used to compare the difference between more than two group means in interval and ordinal variables. Correlations...
were determined using Pearson’s correlation coefficient. The level of statistical significance was set at \( P \) less than 0.05. Test performance was calculated on the basis of the following equations:

\[
\text{Sensitivity (\%)} = \frac{\text{patients with true-positive neuropathy}}{\text{patients with true-positive neuropathy} + \text{patients with false-negative neuropathy}} \times 100.
\]

\[
\text{Specificity (\%)} = \frac{\text{patients with true-negative neuropathy}}{\text{patients with false-positive neuropathy} + \text{patients with true-negative neuropathy}} \times 100.
\]

\[
\text{Positive predictive value (\%)} = \frac{\text{patients with true-positive neuropathy}}{\text{patients with true-positive neuropathy} + \text{patients with false-positive neuropathy}} \times 100.
\]

\[
\text{Negative predictive value (\%)} = \frac{\text{patients with true-negative neuropathy}}{\text{patients with false-positive neuropathy} + \text{patients with true-negative neuropathy}} \times 100.
\]

\[
\text{Diagnostic efficacy (\%)} = \frac{\text{patients with true-positive neuropathy} + \text{patients with true-negative neuropathy}}{\text{all patients}} \times 100.
\]

**Results**

The patient characteristics are presented in Table 4. The ages of the studied patients ranged from 32 to 70 years, and the duration of diabetes ranged from 0.5 to 15 years.

**Results of neurological examination scores for all patients**

The scores (mean ± SD) of all patients, the percentage of patients with abnormal scores, and grading of neuropathic symptoms and deficits are presented in Table 5. Out of 30 patients, nine (30%) had a modified NDS of 6 or more, which indicates an increased risk for foot ulceration.

There were significant correlations between the DNS and modified NSS, DNE, and modified NDS (\( r = 0.81, P < 0.001; r = 0.67, P < 0.001; r = 0.7, P < 0.001 \), respectively), as well as between DNE and modified NSS, and modified NDS (\( r = 0.58, P = 0.001; r = 0.84, P < 0.001 \), respectively). In addition, a significant correlation was found between modified NSS and modified NDS (\( r = 0.64, P < 0.001 \)).

There was a significant correlation between DNS, modified NSS, DNE, modified NDS, and disease duration (\( r = 0.65, P < 0.001; r = 0.6, P < 0.001; r = 0.59, P < 0.001; r = 0.71, P < 0.001 \), respectively), as well as between the DNE and HbA1c (\( r = 0.41, P = 0.008 \)). There was no significant correlation between used scores and patient’s age.

Severity of neurological symptoms and deficits, graded using modified NSS and modified NDS, was significantly correlated with the disease duration (\( r = 0.59, P < 0.001; r = 0.66, P < 0.001 \), respectively), as well as with HbA1c (\( r = 0.48, P = 0.002 \) for both).

**Results of nerve conduction studies**

Comparison between patients with clinically detectable and undetectable neuropathy and the control group showed significant difference between the three groups as regards all parameters of motor NCS except for

---

**Table 4 Patient characteristics**

| variables          | Sex       | Age (years) | Duration of diabetes (years) | Fasting plasma glucose (mg/dl) | 2 h postprandial glucose (mg/dl) | Glycated hemoglobin (HbA1c) (%) | Mode of treatment |
|--------------------|-----------|-------------|------------------------------|-------------------------------|-----------------------------------|---------------------------------|-------------------|
| Sex                | Male      | 2 (6.7)     | 50.6 ± 11.8                  | 146.4 ± 60.9                  | 240 ± 86.6                        | 9.9 ± 2.8                      | Oral hypoglycemic drugs |
|                    | Female    | 28 (93.3)   | 4.6 ± 4.7                    |                               |                                   |                                 | Insulin           |

Data are presented as means ± SD or \( n \) (%).

**Table 5 Neurological examination scores for the studied patients**

| Scores            | Range       | Mean ± SD | Classified as polyneuropathy | Patients [\( N \) (%)] |
|-------------------|-------------|-----------|-------------------------------|------------------------|
| DNS               | 0–4         | 1.6 ± 1.5 | DNS ≥1 point                  | 17 (56.7%)             |
| Modified NSS      | 0–9         | 3.4 ± 3.2 | NSS >1 point                  | 17 (56.7) Mild 2 (11.8) |
|                   |             |           |                               | Moderate 10 (58.8)     |
|                   |             |           |                               | Severe 5 (29.4)        |
| DNE               | 0–10        | 2.4 ± 3.1 | DNE >3 points                 | 8 (26.7) Mild 7 (43.8) |
| Modified NDS      | 0–10        | 3.4 ± 3.7 | NDS >1 point                  | 16 (53.3) Moderate 4 (25) |
|                   |             |           |                               | Severe 5 (31.2)        |

Modified NSS: 3–4, mild symptoms; 5–6, moderate symptoms; 7–10, severe neuropathic symptoms; Modified NDS: 3–5, mild neuropathic deficits; 6–8, moderate neuropathic deficits; 9–10, severe neuropathic deficits; DNE, diabetic neuropathy examination score; DNS, diabetic neuropathy symptom score; NDS, neuropathy disability score; NSS, neuropathy symptom score.
ulnar conduction velocity and tibial and peroneal distal latencies (Table 6).

Similarly, comparison between patients with clinically detectable and undetectable neuropathy and the control group showed significant difference between the three groups as regards all parameters of sensory NCS (Table 7).

**Comparison of neurological scores with nerve conduction studies**
The comparison of neurological scores with NCS is presented in Table 8. According to the results of NCS, 26 patients (86.7%) had polyneuropathy. However, according to the neurological examination scores, 17 patients (56.7%) had polyneuropathy, which means that there were nine cases (30%) of subclinical polyneuropathy.

DNS was found to be the most sensitive test (65.4%), and DNS, DNE, and modified NDS had equal specificity (100%). DNS and modified NDS had a better diagnostic efficacy (70 and 66.7%, respectively) as shown in Table 9.

| Table 6 Comparison between patients with clinically detectable and undetectable neuropathy and the control group as regards parameters of motor nerve conduction studies |
|---|
| **Nerve** | **Parameters** | **Clinically detectable neuropathy (N = 17 patients)** | **Clinically undetectable neuropathy (N = 17 patients)** | **Control group (N = 10)** | **F** | **P** |
| Median | MCV (m/s) | 46.5 ± 6.2 | 51.9 ± 6.5 | 58 ± 7.1 | 9.9 | <0.001* |
|  | DML (ms) | 4.3 ± 1.2 | 3.9 ± 1 | 3 ± 0.5 | 4.5 | 0.02* |
|  | Amp. (mV) | 3.5 ± 1.4 | 3.7 ± 1.9 | 6.3 ± 1.3 | 10.7 | <0.001* |
| Ulnar | MCV (m/s) | 55.1 ± 11 | 59.6 ± 7.3 | 58 ± 7.1 | 0.9 | 0.4 |
|  | DML (ms) | 3.7 ± 0.8 | 3.1 ± 0.8 | 3 ± 0.5 | 3.7 | 0.04* |
|  | Amp. (mV) | 3.4 ± 0.9 | 4.4 ± 1 | 6.3 ± 1.3 | 22.6 | <0.001* |
| Tibial | MCV (m/s) | 43.4 ± 12.4 | 47.2 ± 10.4 | 56.7 ± 6.8 | 4.9 | 0.01* |
|  | DML (ms) | 5.1 ± 1.4 | 4.6 ± 1 | 3.9 ± 0.6 | 3 | 0.06 |
|  | Amp. (mV) | 2.5 ± 2.2 | 2.8 ± 1.3 | 6 ± 0.7 | 15.3 | <0.001* |
| Peroneal | MCV (m/s) | 42.5 ± 12 | 45.7 ± 16.8 | 6.8 ± 2 | 3.9 | 0.03* |
|  | DML (ms) | 6 ± 2.1 | 7.8 ± 9.9 | 3.9 ± 0.6 | 1.3 | 0.3 |
|  | Amp. (mV) | 1.4 ± 1.7 | 1.2 ± 1.3 | 6.7 ± 0.7 | 42.4 | <0.001* |

By one-way analysis of variance test; Data are presented as means ± SD; Amp, amplitude; DML, distal motor latency; MCV, motor conduction velocity; *Significant P-value < 0.05.

| Table 7 Comparison between patients with clinically detectable and undetectable neuropathy and the control group as regards parameters of sensory nerve conduction studies |
|---|
| **Nerve** | **Parameter** | **Clinically detectable neuropathy (N = 17 patients)** | **Clinically undetectable neuropathy (N = 17 patients)** | **Control group (N = 10)** | **F** | **P** |
| Median | SCV (m/s) | 37.2 ± 9.8 | 50.9 ± 8.2 | 53.5 ± 3.4 | 16.5 | <0.001* |
|  | DSL (ms) | 4.2 ± 1.3 | 3.4 ± 1.5 | 2.6 ± 0.5 | 5.4 | 0.009* |
|  | Amp. (μV) | 6.5 ± 6.2 | 13.2 ± 5.9 | 21 ± 3.7 | 21.2 | <0.001* |
| Ulnar | SCV (m/s) | 39.9 ± 7.3 | 50.7 ± 12.5 | 53.5 ± 3.4 | 9.6 | <0.001* |
|  | DSL (ms) | 3.9 ± 1.04 | 3.5 ± 0.9 | 2.6 ± 0.5 | 6.8 | 0.003* |
|  | Amp. (μV) | 6.8 ± 4.6 | 14.3 ± 7.3 | 21 ± 3.7 | 22.2 | <0.001* |
| Sural | SCV (m/s) | 33.2 ± 5.3 | 42.8 ± 4.7 | 50.5 ± 4.4 | 40.7 | <0.001* |
|  | DSL (ms) | 5.5 ± 1.01 | 4.6 ± 0.9 | 4 ± 1 | 7.7 | 0.002* |
|  | Amp. (μV) | 5.2 ± 3.9 | 9.4 ± 2.3 | 17.5 ± 2 | 50.9 | <0.001* |

By one-way ANOVA test; Data are presented as means ± SD; Amp, amplitude; DSL, distal sensory latency; SCV, sensory conduction velocity; *Significant P-value < 0.05.
Modified NDS significantly correlated with median, ulnar, and tibial motor latencies and with median, ulnar, and sural sensory latencies ($r = 0.49, P = 0.001; r = 0.45, P = 0.004; r = 0.44, P = 0.005; r = 0.44, P = 0.004; r = 0.47, P = 0.002; r = 0.44, P = 0.004$, respectively).

HbA1c significantly correlated with tibial motor latency and median sensory latency ($r = 0.48, P = 0.002; r = 0.36, P = 0.02$, respectively).

Both disease duration and HbA1c significantly correlated with the nerve conduction sum score ($r = 0.59, P < 0.001; r = 0.32, P = 0.04$, respectively) (Figs 2 and 3).

### Discussion

The disease process of diabetes causes alterations in the normal nerve functions, which can be reflected either when performing neurological examination, or during electrophysiological testing of the patient. The neurological scores and the electrophysiological studies are used for the diagnosis of the sensorimotor neuropathy. The relations between physiology and pathophysiology emphasize the close interdependence between electrophysiological studies and clinical findings [16].

In the present study, we selected the four neurological scoring systems (DNS, modified NSS, DNE, and modified NDS), which were common and easy to perform, and compared them with NCS, which also has similar advantages. Out of 30 patients with type 2 DM, DSPN was diagnosed clinically (using neurological examination scores) and electrophysiologically (using NCS) in 17 patients (56.7%). However, there were nine cases (30%) of subclinical neuropathy. Subclinical neuropathy indicates the state of electrophysiologically verified neuropathy with the absence of subjective and objective neurological signs. It occurs in about 20% of patients with diabetes [17].

Studies on prevalence of neuropathy in type 2 diabetes had widely differing results, varying from 15 to 50%. The wide variability was attributed to differences in patient sample, diagnostic methods, and criteria adopted for diagnosis [18,19]. Studies that used NCS as a diagnostic marker also reported higher prevalence of neuropathy [20].

The higher prevalence of neuropathy in the present study may be due to the use of NCS for diagnosis of neuropathy, which is a more sensitive method.

In diabetic patients, correlations between various neuropathy tests and scores have previously been reported [13,21]. An association between NSS and NDS has been observed [22].
In the present study, the neurological examination scores significantly correlated with each other, which were similar to results of Meijer et al. [6]. At the

Correlation between neurological examination scores and nerve conduction sum.

Correlation between disease duration and nerve conduction sum.

Correlation between glycosylated hemoglobin (HbA1c) and nerve conduction sum.
same time, the neurological examination scores were significantly correlated with individual variables of NCS. This is in accordance with the study by Meijer et al. [23], in which both scores strongly correlated with electrodagnostic studies. In this study, we added the nerve conduction sum score, which ranged from 1 to 7 based on the involved nerves, and there were significant correlations with DNS, modified NSS, DNE, and modified NDS \( (r = 0.71, P < 0.001; r = 0.58, P < 0.001; r = 0.66, P < 0.001; r = 0.73, P < 0.001, \) respectively).

On comparing NCS with neurological examination scores in each group, it was found that NCS detected more cases of neuropathy (86.7%) compared with neurological examination scores (56.7%). The results showed that both clinical tests and NCS have a role in detecting cases of peripheral neuropathy. The NCS, however, is accurate in the detection of neuropathy as NCS is helpful in detecting subclinical neuropathies as well. Similar results have been obtained by most of the studies. A study by Asad et al. [24] supports the fact that subclinical neuropathy can be detected with NCS. They proved that NCS was more accurate in the detection of neuropathy compared with clinical examination, especially in the subclinical group, although the latter also has its role in the detection of neuropathy.

In Pakistan, Niazi et al. [25] evaluated diabetic polyneuropathy by performing electrodagnostic study on 41 patients. Although clinical examination was carried out in detail, no statistical comparison was made between the clinical findings and NCS. However, it was suggested that these studies are capable of diagnosing diabetic neuropathy even before clinical manifestations, which has been proved in our results.

We assessed the sensitivity and specificity of the four scores taking NCS as the gold standard. DNS was found to be the most sensitive test (65.4%), and DNS, DNE, and modified NDS had equal specificity (100%). DNS and modified NDS had a better diagnostic efficacy (70 and 66.7%, respectively). According to Asad et al. [26], NDS was found to be the most sensitive test (92%) and DNE had the highest specificity (81%). DNS and NSS had a better diagnostic efficacy (76.67%), but DNS sensitivity was 64%, which was similar to that reported in our result. This difference may be due to different geographic area and different races being examined. Meijer et al. [6] also assessed the validity of DNS score against NSS. They did not use NCS. Their results as regards sensitivity and specificity were different from ours. They found high correlation between the two testing methods [6].

The results of both neurological scores and NCS in the present study confirmed the previous findings of greater involvement of the peripheral nervous system in diabetic patients with prolonged disease duration and elevated HbA1c [27]. Moreover, the severity of neurological symptoms and deficits was significantly correlated with the disease duration \( (r = 0.59, P < 0.001; r = 0.66, P < 0.001, \) respectively), as well as with HbA1c \( (r = 0.48, P = 0.002 \) for both).

In conclusion, neurological examination scores can detect and grade neuropathy in majority of cases. However, NCS was accurate for the detection of DSPN, especially subclinical neuropathies. Therefore, we can use each, NCS or neurological examination scores, for detecting and grading diabetic neuropathy and using both gives us a better chance for earlier diagnosis.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Dyck PJ, Lais A, Kames JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19:425–439.
2. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15:1902–1925.
3. England JD, Gronseth GS, Franklin G, Miller RG, Aasbury AK, Carter GT, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199–207.
4. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011; 27:620–628.
5. Barbano R, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. Pharmacotherapy of painful diabetic neuropathy. Curr Pain Headache Rep 2003; 7:169–177.
6. Meijer JW, Smit AJ, Sondener EV, Groothoff JW, Elsmra WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med 2002; 19:962–965.
7. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1986; 11:21–32.
8. International Expert Committee. International Expert committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327–1334.
9. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl 1):S14–S80.
10. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150–154.
11. Meijer JW, van Sondener E, Blauuwzweikel EE, Smit AJ, Groothoff JW, Elsmra WH, Links TP. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care 2000; 23:760–763.
12. Boulton A. Management of diabetic peripheral neuropathy. Clin Diabetes 2005; 23:9–15.
13 Dyck PJ, Karnes JL, O’Brien PC, Litchy WJ, Low PA, Melton LJ. 3rd. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992; 42:1164–1170.

14 Albers JW, Brown MB, Sima AA, Greene DA. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Toxirestat Study Group for the Early Diabetes Intervention Trial. Neurology 1996; 46:85–91.

15 American Diabetes Association, American Academy of Neurology. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care 1988; 11:592–597.

16 Kraup C. Nerve conduction studies in selected peripheral nerve disorders. Curr Opin Neurol 2002; 15:579–593.

17 Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, (editors). Williams textbook of endocrinology. chapter 2. 11th ed. London: Saunders; 2007.

18 Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1994; 17:1172–1177.

19 Mythili A, Kumar KD, Subrahmanyam KA, Venkateswaru K, Butchi RG. A Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy. Int J Diabetes Ctries 2010; 30:43–48.

20 Kumar S, Ashe HA, Parnell LN, Fernando DJ, Tsigos C, Young RJ, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med 1994; 11:480–484.

21 Dyck PJ, Bushek W, Spring EM, Karnes JL, Litchy WJ, O’Brien PC, Service FJ. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 1987; 10:432–440.

22 Dyck PJ, Karnes JL, Daube J, O’Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 1985; 108 (Pt 4):861–880.

23 Meijer JW, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care 2003; 26:697–701.

24 Asad A, Hameed MA, Khan UA, Butt MU, Ahmed N, Nadeem A. Comparison of nerve conduction studies with diabetic neuropathy symptom score and diabetic neuropathy examination score in type-2 diabetics for detection of sensorimotor polyneuropathy. J Pak Med Assoc 2009; 59:594–598.

25 Nazi PHK, Ahmad K, Hussain A, Butt AW, Alam A. Electrodiagnostic evaluation of diabetic polyneuropathy. Pak Armed Forces Med J 2001; 51:75–77.

26 Asad A, Hameed MA, Khan UA, Ahmed N, Butt MU. Reliability of the neurological scores for assessment of sensorimotor neuropathy in type 2 diabetics. J Pak Med Assoc 2010; 60:166–170.

27 Perkins BA, Zinman B, Olyeye D, Bri1 V. Simple screening tests for peripheral neuropathy in the diabetic clinic. Diabetes Care. 2001; 24:250–256.